

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated

RRID:AB_331460

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9111, RRID:AB_331460

Antibody Information

URL: http://antibodyregistry.org/AB_331460

Proper Citation: Cell Signaling Technology Cat# 9111, RRID:AB_331460

Target Antigen: cdc2, phospho (Tyr15)

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10104768, AB_10104769, AB_10835695, AB_2074655, AB_331460.

Antibody Name: Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated

Description: This unknown targets cdc2, phospho (Tyr15)

Target Organism: monkey, rat, simian, xenopus, mouse, human

Antibody ID: AB_331460

Vendor: Cell Signaling Technology

Catalog Number: 9111

Record Creation Time: 20250819T233629+0000

Record Last Update: 20250820T055138+0000

Ratings and Alerts

No rating or validation information has been found for Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated.

No alerts have been found for Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Haykal MM, et al. (2025) Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers. Cancer letters, 620, 217665.

Kirichenko E, et al. (2025) Jub-induced phosphorylation of Warts inhibits its activity and recruitment into biomolecular condensates. Cell reports, 44(12), 116647.

Marotta VE, et al. (2025) OTUD6B regulates KIFC1-dependent centrosome clustering and breast cancer cell survival. EMBO reports, 26(4), 1003.

Tan T, et al. (2025) Revisiting phosphoregulation of Cdc25C during M-phase induction. iScience, 28(1), 111603.

Takacs L, et al. (2025) Evidence of substrate control of Cdk phosphorylation during the budding yeast cell cycle. Cell reports, 44(4), 115534.

Joo YK, et al. (2025) The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation. Cell reports, 44(8), 116019.

Drainas AP, et al. (2024) GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer. Cell reports, 43(8), 114606.

Lim JS, et al. (2024) Energy?stress?mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple?negative breast cancer. Oncology reports, 52(2).

Santoni M, et al. (2024) Unraveling the interplay between PKA inhibition and Cdk1 activation during oocyte meiotic maturation. Cell reports, 43(2), 113782.

Dreyer J, et al. (2024) Acute multi-level response to defective de novo chromatin assembly in S-phase. Molecular cell, 84(24), 4711.

Xu N, et al. (2023) PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C. Cell reports, 42(9), 113041.

Petrosius V, et al. (2023) Temporal phosphoproteomics reveals WEE1-dependent control of 53BP1 pathway. iScience, 26(1), 105806.

Zhou C, et al. (2022) The oocyte spindle midzone pauses Cdk1 inactivation during fertilization to enable male pronuclear formation and embryo development. Cell reports, 39(5), 110789.

Elbæk CR, et al. (2022) WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. *Cell reports*, 38(3), 110261.

Donker L, et al. (2022) A mechanical G2 checkpoint controls epithelial cell division through E-cadherin-mediated regulation of Wee1-Cdk1. *Cell reports*, 41(2), 111475.

Bose A, et al. (2021) 14-3-3 γ prevents centrosome duplication by inhibiting NPM1 function. *Genes to cells : devoted to molecular & cellular mechanisms*, 26(6), 426.

Klomp JE, et al. (2021) CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. *Cell reports*, 37(9), 110060.

Branigan TB, et al. (2021) MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. *Cell reports*, 34(9), 108808.

Kamenz J, et al. (2021) Bistable, Biphasic Regulation of PP2A-B55 Accounts for the Dynamics of Mitotic Substrate Phosphorylation. *Current biology : CB*, 31(4), 794.

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. *Cell reports. Medicine*, 2(9), 100394.